Successful Neoadjuvant Chemotherapy for Small-Cell Neuroendocrine Carcinoma of the Pancreas: A Case Report

Abstract

Neoadjuvant therapy for pancreatic neuroendocrine tumors may potentially aid downstaging, increase the possibility of radical surgery. We herein report a case of a 63-year-old man who had been diagnosed with locally advanced small-cell neuroendocrine carcinomas of the pancreas according to the diagnostic biopsy. The patient received 6 courses of etoposide and cisplatin as neoadjuvant therapy in an attempt to stop tumor progression, which promoted obvious tumor shrinkage without adverse effects and allowed subsequent Appleby procedure, the distal pancreatectomy with celiac artery resection. The patient showed no recurrence in the follow-up of a contrast-enhanced computed tomographic scan, which is 8 months after surgery. To the best of our knowledge, this is a rare case to report etoposide and cisplatin administration before surgery for unresectable pancreatic neuroendocrine carcinoma promoted a pathological partial response and finally achieved a radical surgery, providing a novel therapeutic option for patients with locally advanced pancreatic neuroendocrine carcinoma.

Graph Attention Networks for Drug Combination Discovery: Targeting Pancreatic Cancer Genes with RAIN Protocol

“…survival rate of 14 months. [120], [121], [122], [123] The GNP regimen, which denotes The combination of gemcitabine and nab-paclitaxel constitutes a chemotherapy regimen approach utilized for treating advanced pancreatic cancer. It involves two small molecule drugs: Gemcitabine, a a pyrimidine analog and antimetabolite compound that becomes part of the DNA structure, impeding the creation of DNA; nab-Paclitaxel, a unique version of the antineoplastic agent paclitaxel bound to albumin, inhibiting cell division.…”

“…Recent studies highlight the affinity of Octreotide nanoparticles for in vivo induction of pancreas ductal adenocarcinoma using MIA Paca-2, indicating its potential utility in targeted therapy for pancreatic cancer. [121], [178], [187], [188] Leucovorin, classified as a folic acid analog, shares similarities with the vitamin folic acid, crucial for new cell production and maintenance. When combined with specific chemotherapy drugs, Leucovorin enhances their efficacy in eradicating cancer cells or mitigating adverse side effects.…”

“…Recent studies highlight the affinity of Octreotide nanoparticles for in vivo induction of pancreas ductal adenocarcinoma using MIA Paca-2, indicating its potential utility in targeted therapy for pancreatic cancer. [121], [178], [187], [188]…”